Microarray technology to the fore

November 1, 2010

Innovative and reconfigured platforms help researchers maximize genomic studies

Read the full article

Innovative Protein-Expression Systems

September 6, 2010

There has been a maturation of the bioprocessing industry as companies have moved away from a focus on anticancer biologics toward a more diversified portfolio of pharmacological agents.

Read the full article

LC/MS Solidifying Key Role in Clinical Labs

September 6, 2010

Gas or liquid chromatography combined with mass spectrometry is widely recognized as a versatile and powerful technique for the investigation of complex chemical mixtures. A state-of-the-art accounting of progress in this area took place recently in Hong Kong at the conference on “New Horizons in Clinical
Chemistry.”

Read the full article

Emerging Label-Free Technologies

September 6, 2010

Cell-based assays are powerful tools for monitoring response to external activation signals in living cells. Recognition of this fact has been responsible for roughly 40% growth in the industry in 2008, according to SMI Conferences, which recently sponsored a symposium on the topic.

Read the full article

Targeted Resequencing Improves Precision

September 6, 2010

Using next-generation sequencing for clinical diagnostic purposes offers unique challenges due to the complexity of the technology and data analysis issues. Presentations at “Now Generation Sequencing” will discuss how to streamline technical processes and bioinformatics analyses to rapidly move this technology into the clinic.

Read the full article

Mass Spec Central to Metabolomics

September 6, 2010

The emerging field of metabolomics would be hobbled by irresolvable technical challenges were it not for the expanding availability of user-friendly and affordable mass spec instruments.popularity, and it is now a mainstream industrial tool.

Read the full article

DNA Vaccines Hit their Stride with More Approvals Anticipated

September 6, 2010

The DNA vaccines field is definitely regaining the momentum that it had a few years ago, according to David Weiner, Ph.D., professor of pathology and laboratory medicine at the University of Pennsylvania and chair of the “DNA Vaccines” meeting held last month in New Orleans.

Read the full article

Mass Spectrometry’s Role in Discovery on the Rise

September 6, 2010

The “Ion Chemistry and Mass Spectrometry Conference” held at Lake Arrowhead, CA, earlier this year, covered many advances in mass spectrometry that have allowed unprecedented analysis of molecular events occurring in normal and pathological biomolecular systems.

Read the full article

Multiplexing Advances Redefine HTS

September 6, 2010

Multiplexing is a critical component of rapid screening technologies. At the annual meeting of the Society for Biomolecular Sciences held recently in Phoenix, a number of industry and academic scientists explained their pursuit of novel technologies that allow assays to be performed simultaneously on each well of a microtiter plate. Label-free technologies such as surface plasmonresonance (SPR) are available through various companies, and several contract research organizations are adept at their application.

Read the full article

About Us

Newport Biotechnology Consultants, founded in 2005, originally was aimed at providing writing expertise in the life sciences industry, with a specialization in molecular immunology. I drew upon my academic and industrial background to cover new developments and technologies in antibody therapies and related areas of biotechnology. These reviews were published in a number of trade journals, especially articles in Genetic Engineering and Biotechnology News (see articles). More recently I have expanded my writing into other fields, including emergency management, drug discovery, bioprocessing, environmental and sustainable technologies, micro- and nanotechnology and many other areas. I also am involved in regulatory issues. I am Chair of the Meridian Bioscience Institutional Biosafety Committee, and I am a member of the Cincinnati Children’s Medical Center Institutional Biosafety Committee (see consulting services). Both IBCs review research protocols dealing with the use of recombinant DNA. Finally, I have consulted for a number of companies on laboratory design, business plan evaluation and regulatory questions.

Videos, Slideshows and Podcasts by Cincopa Wordpress Plugin